New therapeutic concepts against ischemia-reperfusion injury in organ transplantation
Introduction Ischemia-reperfusion injury (IRI) involves a positive amplification feedback loop
that stimulates innate immune-driven tissue damage associated with organ procurement …
that stimulates innate immune-driven tissue damage associated with organ procurement …
Genetic and life style risk factors for recurrent non-alcoholic fatty liver disease following liver transplantation
S Iacob, S Beckebaum, R Iacob, C Gheorghe… - Frontiers in …, 2022 - frontiersin.org
Recurrent or de novo non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis
(NASH) following liver transplantation (LT) is a frequent event being increasingly recognized …
(NASH) following liver transplantation (LT) is a frequent event being increasingly recognized …
HBsAg seroconversion in de novo hepatitis B virus‐infected paediatric liver transplant recipients with anti‐viral therapy
C Dong, Z Song, C Sun, K Wang, J Chen… - Journal of Viral …, 2022 - Wiley Online Library
We investigated the clinical characteristics and therapeutic strategies for paediatric liver
transplant (PLT) recipients who experienced de novo hepatitis B virus infection and the …
transplant (PLT) recipients who experienced de novo hepatitis B virus infection and the …
Liver Allograft Cirrhosis, Retransplant, and Mortality Secondary to Recurrent Disease After Transplant for MASH: A Systematic Review and Meta-analysis
Background. Recurrent disease after liver transplant is well recognized for many diseases.
Metabolic dysfunction–associated steatotic liver disease (MASLD) and steatohepatitis …
Metabolic dysfunction–associated steatotic liver disease (MASLD) and steatohepatitis …
NAFLD in Liver Transplant Recipients
L Yuan, N Terrault - Need-to-Know NAFLD, 2024 - taylorfrancis.com
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases
globally, and NAFLD-associated cirrhosis is becoming a leading indication for liver …
globally, and NAFLD-associated cirrhosis is becoming a leading indication for liver …
Metabolická a genetická rizika vzniku a rozvoje nealkoholové tukové choroby jater u pacientů po transplantaci jater a její význam pro přežívání pacientů a štěpů
I Míková - 2022 - dspace.cuni.cz
Nealkoholová tuková nemoc jater (NAFLD) se často vyskytuje nejen v obecné populaci, ale
iu pacientů po transplantaci jater (LT). Data o prevalenci, vývoji, příčinách a významu …
iu pacientů po transplantaci jater (LT). Data o prevalenci, vývoji, příčinách a významu …